CVS Health reported second-quarter net income of $2.9 billion on Aug. 5, a roughly threefold increase from the same quarter a year earlier as the company said it has begun to rein in rising costs within its Aetna health plans.
Improving medical-cost metrics
The company said the medical benefits ratio — the share of premiums paid out for medical care — fell to 87.4% from 89.9% in the prior-year quarter. CVS attributed the improvement primarily to better underlying performance in its government business and the absence of a premium deficiency reserve that had been recorded in the previous year.
Executives said the stronger-than-expected operating results led them to lift full-year diluted earnings-per-share guidance to a range of $6.84 to $7.04, up from a prior range of $6.24 to $6.44. It is the second straight quarter in which management increased its EPS outlook.
“As our businesses work together to deliver a technology-powered care engagement experience, we continue to deliver strong performance,” said David Joyner, chief executive officer, in a statement accompanying the quarterly results.
Management tightening the reins
The gains come amid a multi-quarter push by CVS leadership to stabilise costs across its diversified healthcare operations since the promotion of its CEO nearly two years ago. The company said performance gains reflect a combination of cross-business collaboration and operational changes aimed at delivering more integrated, convenient care.
CVS highlighted that the decline in the medical benefits ratio was driven in part by improved results within government-related business lines and by the absence of a previous-year reserve. The company has faced pressure, along with other insurers, to manage rising medical spending among plan members — a challenge pronounced in Medicare Advantage lines that serve older adults.
Key figures
- Net income (Q2): $2.9 billion (nearly triple year-over-year)
- Medical benefits ratio: 87.4% (vs. 89.9% year-ago)
- Updated diluted EPS guidance (2026): $6.84–$7.04 (raised from $6.24–$6.44)
| Metric | Current | Prior-period / Prior guidance |
|---|---|---|
| Medical benefits ratio (Q2) | 87.4% | 89.9% |
| Diluted EPS guidance (2026) | $6.84–$7.04 | $6.24–$6.44 |
Broader implications
The results underscore the financial importance of managing utilisation and costs in health-plan portfolios, particularly among older patient populations enrolled in Medicare Advantage. Insurers across the industry have been grappling with growing medical claims, and improvements in benefit ratios can materially boost profitability without necessarily increasing premiums.
For CVS, which combines pharmacy, clinic and insurance assets, the company framed the results as validation of a strategy to link technology and care delivery to produce a more seamless experience for patients and plan members. The firm suggested that better coordination across its businesses can produce both clinical and financial benefits.
Investors have been watching the performance of CVS closely since leadership changes began, and management’s repeated upward revisions to earnings guidance indicate confidence that recent operational gains are durable. However, the company noted that some of the improvement reflected the non-recurrence of a reserve taken in the previous year, a factor that may not recur in future quarters.
As CVS moves forward, how sustained reductions in the medical benefits ratio are — and whether those reductions are achieved through lower utilisation, price negotiation, or care-delivery changes — will be central to assessing the company’s longer-term trajectory in the health-insurance market.
